Zota Health Care converts Rs 119.5 crore loan into 235,512 shares of Davaindia Health Mart

What Zota Health Care announced

On July 17, 2026, Zota Health Care Limited (ticker ZOTA) filed an intimation with the National Stock Exchange stating that it had acquired 235,512 equity shares of its wholly‑owned subsidiary M/s Davaindia Health Mart Limited. The acquisition was executed on a preferential basis and the consideration was not cash; instead, it involved the conversion of an outstanding unsecured loan together with accrued interest owed by the subsidiary to the parent.

The filing, made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, explains that the transaction is aimed at adjusting and discharging the loan, thereby reducing the Group’s total debt and enhancing its net‑worth.

Details of the acquisition

• Target entity: Davaindia Health Mart Limited, incorporated on 1 January 2020, operates a retail generic pharmacy chain under a Company‑Owned‑Company‑Operated (COCO) model.
• Business footprint: As of 30 June 2026, the subsidiary runs 1,855 stores across India, offering more than 2,000 SKUs that include medicines, Ayurvedic products, cosmetics, nutraceuticals and OTC items.
• Financial profile: The audited FY 2025‑26 turnover of Davaindia was Rs 267.71 crore; paid‑up share capital stood at Rs 2.71 crore.
• Related‑party status: The acquisition does not fall within related‑party transactions. The promoter group holds no interest in the subsidiary, and the deal was conducted at arm’s length.
• Regulatory approvals: No governmental or regulatory approvals were required for the transaction.

Financial terms and pricing

The consideration for the 235,512 shares was Rs 1,19,52,23,400 (approximately Rs 119.5 crore). This amount reflects the conversion of the outstanding unsecured loan and its accumulated interest into equity. The per‑share cost was Rs 5,075, which includes a premium of Rs 5,065 per share.

The conversion effectively writes off the loan from the subsidiary’s books as of 15 June 2026, the date on which the loan balance was recorded. By converting debt into equity, Zota expects a reduction in consolidated debt and an improvement in the Group’s net‑worth, without any cash outflow.

Shareholding and control post‑transaction

Even after acquiring the additional shares, Davaindia Health Mart Limited continues to be a wholly‑owned subsidiary of Zota Health Care. The acquisition does not alter the existing control structure; it merely changes the composition of the subsidiary’s equity by replacing debt with shares.

The transaction does not trigger any change in voting rights or management control, as the parent already holds 100 % of the subsidiary’s equity. Consequently, there is no dilution for existing shareholders of Zota Health Care.

Key facts at a glance

Why this matters for investors

The acquisition is a balance‑sheet restructuring move. By converting a sizable unsecured loan into equity, Zota reduces its consolidated debt burden, which can improve leverage ratios and potentially lower interest costs in the future. The transaction also enhances the net‑worth of the Group without diluting existing shareholders, as the subsidiary remains wholly owned.

From an operational perspective, the subsidiary’s strong growth trajectory—evident from the jump in turnover from Rs 44.77 crore in FY 2023‑24 to Rs 267.71 crore in FY 2025‑26—suggests that the parent is retaining a valuable asset. The move therefore aligns the capital structure with the subsidiary’s expanding business, supporting further expansion of its 1,855‑store pharmacy network.

Investors should note that the deal does not involve cash outflow, and no new equity was issued to external parties. Consequently, there is no immediate dilution or cash‑flow impact on the listed company’s balance sheet.

Conclusion

Zota Health Care Limited has completed the conversion of an unsecured loan and accrued interest into 235,512 equity shares of its subsidiary Davaindia Health Mart Limited, valuing the transaction at roughly Rs 119.5 crore. The subsidiary remains a wholly‑owned entity, and the restructuring is expected to lower the Group’s debt and improve net‑worth. No further regulatory approvals are pending, and the transaction does not affect existing shareholder dilution.

The acquisition was finalized on 17 July 2026, and the shares were issued on a preferential, non‑cash basis.